X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs ABBOTT INDIA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD ABBOTT INDIA BIOCON LTD/
ABBOTT INDIA
 
P/E (TTM) x 78.0 43.5 179.1% View Chart
P/BV x 7.3 10.9 67.5% View Chart
Dividend Yield % 0.2 0.6 27.4%  

Financials

 BIOCON LTD   ABBOTT INDIA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
ABBOTT INDIA
Mar-16
BIOCON LTD/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,1626,015 19.3%   
Low Rs4833,707 13.0%   
Sales per share (Unadj.) Rs194.61,236.9 15.7%  
Earnings per share (Unadj.) Rs34.4122.2 28.2%  
Cash flow per share (Unadj.) Rs48.3129.0 37.4%  
Dividends per share (Unadj.) Rs1.0035.00 2.9%  
Dividend yield (eoy) %0.10.7 16.9%  
Book value per share (Unadj.) Rs241.9521.2 46.4%  
Shares outstanding (eoy) m200.0021.25 941.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.23.9 107.5%   
Avg P/E ratio x23.939.8 60.1%  
P/CF ratio (eoy) x17.037.7 45.2%  
Price / Book Value ratio x3.49.3 36.4%  
Dividend payout %2.928.6 10.1%   
Avg Mkt Cap Rs m164,440103,296 159.2%   
No. of employees `0009.23.0 312.4%   
Total wages/salary Rs m7,4703,370 221.7%   
Avg. sales/employee Rs Th4,213.98,891.8 47.4%   
Avg. wages/employee Rs Th809.01,140.0 71.0%   
Avg. net profit/employee Rs Th745.2878.3 84.8%   
INCOME DATA
Net Sales Rs m38,91126,284 148.0%  
Other income Rs m1,571504 311.5%   
Total revenues Rs m40,48226,789 151.1%   
Gross profit Rs m9,7953,665 267.2%  
Depreciation Rs m2,772144 1,919.7%   
Interest Rs m2608 3,209.9%   
Profit before tax Rs m8,3344,017 207.5%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6161,421 113.7%   
Profit after tax Rs m6,8812,596 265.0%  
Gross profit margin %25.213.9 180.5%  
Effective tax rate %19.435.4 54.8%   
Net profit margin %17.79.9 179.0%  
BALANCE SHEET DATA
Current assets Rs m40,47714,446 280.2%   
Current liabilities Rs m16,7834,725 355.2%   
Net working cap to sales %60.937.0 164.6%  
Current ratio x2.43.1 78.9%  
Inventory Days Days6051 116.0%  
Debtors Days Days8320 423.6%  
Net fixed assets Rs m45,0731,113 4,050.0%   
Share capital Rs m1,000213 470.6%   
"Free" reserves Rs m47,37710,808 438.4%   
Net worth Rs m48,37711,076 436.8%   
Long term debt Rs m21,0820-   
Total assets Rs m93,94216,241 578.4%  
Interest coverage x33.1497.0 6.7%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.41.6 25.6%   
Return on assets %7.616.0 47.4%  
Return on equity %14.223.4 60.7%  
Return on capital %12.636.3 34.7%  
Exports to sales %00.6 0.0%   
Imports to sales %012.6 0.0%   
Exports (fob) Rs mNA162 0.0%   
Imports (cif) Rs mNA3,322 0.0%   
Fx inflow Rs m12,988268 4,846.3%   
Fx outflow Rs m7,8993,927 201.1%   
Net fx Rs m5,089-3,659 -139.1%   
CASH FLOW
From Operations Rs m6,4002,514 254.5%  
From Investments Rs m-4,985-800 623.5%  
From Financial Activity Rs m-1,775-803 221.1%  
Net Cashflow Rs m-473912 -51.9%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 7.9 106.3%  
FIIs % 10.7 0.1 10,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.1 116.4%  
Shareholders   109,995 18,270 602.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   PANACEA BIOTECH  DISHMAN PHARMA  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 19, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS